Arthrex Eclipse™ Shoulder Prosthesis

• ClinicalTrials.gov Identifier: NCT01790113
• Recruitment Status: Terminated
• First Posted: February 13, 2013
• Results First Posted: January 29, 2021
• Last Update Posted: February 3, 2021
• Sponsor: Arthrex, Inc.
• Information provided by (Responsible Party): Arthrex, Inc.

Study Description

Brief Summary:

A Prospective, Randomized, Multicenter Study comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder to the Univers™ II Shoulder Prosthesis in patients with a degenerative joint disease.

Condition or disease	Intervention/treatment	Phase
Osteoarthritis	Device: Univers™; Device: Eclipse™ Total Shoulder Replacement	Not Applicable

Detailed Description:

The purpose of this study is to demonstrate non-inferiority of the Arthrex Eclipse™ Shoulder Prosthesis to the Arthrex Univers™ II Shoulder Prosthesis for the treatment of degenerative joint disease in subjects who are candidates for total shoulder replacement. Non-inferiority in terms of safety and effectiveness will be measured by a 2 year composite clinical success (CCS) that requires functional improvement, radiographic success, absence of reoperations and revision, and lack of serious device-related adverse events.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 303 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Prospective, Randomized, Multicenter Study Comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder Prothesis to the Univers™ II Shoulder Prosthesis in Patients With a Degenerative Joint Disease
• Actual Study Start Date: February 4, 2013
• Actual Primary Completion Date: June 7, 2019
• Actual Study Completion Date: June 7, 2019

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Univer™ II; Univers™ II Total Shoulder Replacement	Device: Univers™; Control
Experimental: Eclipse™; Eclipse™ Total Shoulder Replacement	Device: Eclipse™ Total Shoulder Replacement; Investigational

Outcome Measures

Primary Outcome Measures :

1. Composite Clinical Success [ Time Frame: 2 year ]

   To be considered a success, the eclipse subject must meet the following composite clinical success criteria:

   1. An improvement in the Adjusted Constant Score (for pain, Function, and range of motion) from baseline (pre-op) to the 24 month time-point that is > or = to 10 and a final Adjusted Constant Score > or + to 54.
   2. Radiographic success at the Month 24 time-point which is defined as absence of clinically significant humeral radiolucency, humeral migration/subsidence (relative to 3 month time-point), glenoid migration/subsidence (relative to the 3 month time-point), device disassembly or fracture, and/or periprosthetic fracture, as described in the radiographic protocol.
   3. No reoperation, removal or modification of any study component up to the subject's completion of the study.
   4. No serious device-related complications up to the subject's completion of the study.

Eligibility Criteria

• Ages Eligible for Study: 21 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• The subject is > 21 years of age
• The subject has continued symptoms in target shoulder despite at least 3 months of other treatment modalities(e.g.: anti-inflammatory, physical therapy and steroid injections)
• The subject has a diagnosis in the target shoulder of one or more of the following:

osteoarthritis, avascular necrosis, post-traumatic arthritis, or rheumatoid arthritis.

• The subject presents with pain and functional impairment in the index shoulder, measured by an Adjusted Constant Score of ≤50. Note: The Adjusted Constant Score will be calculated from the raw Constant Score to establish patient eligibility.
• The subject is willing to receive implantation of the Arthrex™ Shoulder Prosthesis or Univers™ II Shoulder Prosthesis.
• The subject must be physically and mentally willing and able to comply with all study procedures (including follow-up visits and radiographic assessments) until the conclusion of the study.
• The subject has been informed of the nature of the study and provided written consent as approved by the sites local Institutional Review Board or Ethic Review Board.

Exclusion Criteria:

• The subject is likely a candidate for hemi-humeral arthroplasty (i.e.: Avascular Necrosis of the humeral head without glenoid involvement (Stages 0-3): Rotator Cuff Deficient Shoulder: Glenoid Bone deficiency/deformity that precludes glenoid replacement (Walch Type B2 or C) or Fractures of the Proximal Humerus, without Glenoid involvement.
• The subject has immature bone as defined by the absence of cancellous bone patterning, a mature, thick cortex, and stress lines within the cancellous bone.
• The subject has obvious defects in bone quality, such as cysts or lesions, in the humeral head of the target shoulder, as demonstrated by radiographic evaluation.
• The subject has a target shoulder a rotator cuff that is not intact and not reconstructible.
• The subject has Irreducible 3- and 4- part proximal humeral fractures of the target shoulder.
• The subject has documented history of foreign-body sensitivity.
• Subject with positive pregnancy test, or lactating, or intends to become pregnant during treatment period
• The subject has history of Schizophrenia, Bipolar Disorder and/or Major Depressive Disorder as defined by DSM IV.
• The subject is skeletally immature demonstrated radiographically by incomplete closure of proximal humeral epiphyses.
• The subject is at high risk for poor healing or confounding outcomes [(i.e.: clinically significant renal, hepatic, cardiac hematologic disease or endocrine disease)]
• The subject is on immune-stimulating or immunosuppressive agents
• The subject has co-morbidity that reduces life expectancy < 36 month.
• The subject seeking or receiving workman's compensation for shoulder injury,
• The subject is > 350 lbs.
• The subject engaged in heavy labor (e.g. repetitive lifting in the excess of more than 50 lbs.)
• The subject has had surgery in the affected shoulder in the last 12 months (with the exception of diagnostic arthroscopy without reconstruction or repair procedures)
• The subject is engaged in active sports participation. (e.g. weight lifting involving upper extremities or involved in contact sports)
• The subject is taking medications known to potentially interfere with bone/soft tissue healing (e.g. steroids with the exception of topical and/or inhalers)
• The subject is a prisoners or wards of the state
• The subject has a history of alcohol and/or substance abuse as defined by DSM IV (Diagnostic and Statistical Manual Diploma in Social Medicine)
• The subject has an active or chronic infection, either systemic or local.
• The subject has pathologic fractures of the affected shoulder
• The subject has acute trauma of the affected shoulder
• The subject has osteoporosis defined as a bone density T score of < or = -2.5. (A screening Questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation) and MORES (Male Osteoporosis Risk Estimation Score), will be used to screen patients who require a DEXA (dual energy x-ray absorptiometry) bone mineral density measurement.

Contacts and Locations

Locations

United States, Arizona

Banner Research

Sun City, Arizona, United States, 85351

United States, California

Orthopedics Stanford University

Redwood City, California, United States, 94063

United States, Colorado

Western Orthopaedics

Denver, Colorado, United States, 80218

United States, Illinois

Midwest Orthopaedics at Rush

Chicago, Illinois, United States, 60612

United States, Kentucky

Ellis and Badenhausen Orthopedics PSC

Louisville, Kentucky, United States, 40223

United States, Maryland

Medstar Health Research Institute

Hyattsville, Maryland, United States, 20782

Peninsula Orthopaedics Associates, P.A.

Salisbury, Maryland, United States, 21804

United States, Minnesota

Essentia Health Duluth

Duluth, Minnesota, United States, 55805

United States, New York

Excelsior Orthopedics

Amherst, New York, United States, 14226

SUNY Upstate Medical Universtiy

East Syracuse, New York, United States, 13057

United States, Ohio

Adena Health System

Chillicothe, Ohio, United States, 45601

OhioHealth Research Institute at Grant Medical Center

Columbus, Ohio, United States, 43215

United States, Oregon

Southern Oregon Orthopedics

Medford, Oregon, United States, 97504

United States, Pennsylvania

University Orthopedics

Altoona, Pennsylvania, United States, 16602

Rothman Institute

Philadelphia, Pennsylvania, United States, 19108

United States, South Carolina

Palmetto Health Orthopedics (formerly Providence Orthopedics Group, LLC_Moore Orthopedics)

Columbia, South Carolina, United States, 29203

Sponsors and Collaborators

Arthrex, Inc.

Investigators

• Study Director: Melissa Hirschberg; Arthrex, Inc.

  Study Documents (Full-Text)

Documents provided by Arthrex, Inc.:

Study Protocol and Statistical Analysis Plan  [PDF] August 15, 2019

More Information

• Responsible Party: Arthrex, Inc.
• ClinicalTrials.gov Identifier: NCT01790113
• Other Study ID Numbers: Arthrex 003
• First Posted: February 13, 2013
• Results First Posted: January 29, 2021
• Last Update Posted: February 3, 2021
• Last Verified: October 2019

Additional relevant MeSH terms:

Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases